Baker Bros. Advisors LP Arcus Biosciences, Inc. Transaction History

Baker Bros. Advisors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $1.9 Million - $3.01 Million	-72,709 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $726,172 - $1.38 Million	-42,716 Reduced 37.01%	72,709 $1.89 Million
Q3 2020 Nov 16, 2020	SELL	$17.14 - $25.47 $104,708 - $155,596	-6,109 Reduced 5.03%	115,425 $1.98 Million
Q2 2018 Aug 14, 2018	BUY	$12.24 - $17.05 $1.49 Million - $2.07 Million	121,534 New	121,534 $1.49 Million

186

49.2M

204K

149K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.